LYNPARZA (olaparib)

LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3

Prescribing Information

Safety and Tolerability

The safety and tolerability of Lynparza are acceptable for oral maintenance treatment administration.4

The most common adverse events associated with Lynparza monotherapy for patients identified with BRCAm were nausea, fatigue and vomiting and were generally mild to moderate (grade 1 or 2) in severity. The most common Grade 3 and 4 adverse events reported for Lynparza vs placebo in the BRCAm population were fatigue (7% vs 2%) and anaemia (5% vs 2%), neutropenia (4% vs 2%) and vomiting (3% vs 0%).3,4

Table showing most common adverse events associated with Lynparza monotherapy for patients identified with BRCAm
Table showing most common adverse events associated with Lynparza monotherapy for patients identified with BRCAm